GSK Expands AI Footprint with $70M Tempus Deal - Updated 0 18.10.2022 03:00 Feedity.com GlaxoSmithKline (GSK) announced Tuesday morning it has struck a $70 million deal with Tempus in exchange for expanded access to Tempus’ AI-based patient data platform. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
